

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Rheumatoid arthritis - tocilizumab (rapid review TA198)

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

None identified.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

None identified.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

None identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendations expand the recommendations to a wider patient

population, compared to technology appraisal 198: tocilizumab for the treatment of rheumatoid arthritis. This does not relate to any specific group versus others listed in the equality legislation and Committee therefore considered that there were no equality issues.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

No

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

None were raised at any stage of this appraisal. The ACD table reflects that Committee considered if there were any further issues at its Appraisal Committee meetings.

Approved by Associate Director (name): Frances Sutcliffe 24/11/2011

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

None identified.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

None identified.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

None identified.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

None identified.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 01/12/2011